Clinical Trial for Everolimus Shows Decreased Tumor Volume for Patients With Benign Kidney Tumors
PHILADELPHIA (April 21, 2020)—A clinical trial headed by Fox Chase Cancer Center physicians has found that patients with certain common benign, spontaneous kidney tumors saw a marked decrease in tumor volume after being treated with the drug everolimus, also known by its brand name, Afinitor. Until this study, there were no data on whether the drug was effective and safe for patients with the tumors who don’t have angiomyolipomas.